On September 11, 2023, Dianthus Therapeutics, Inc. closed the transaction. The company has received $71.987749 million private investment for the issuance of 2,873,988 common stock at a purchase price $23.34 per share for a gross proceeds $67.07888 million and 210,320 pre-funded warrants at a purchase price $23.34 per warrant for a gross proceeds of $4.908869 million in the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.77 USD | -5.55% | -15.06% | +109.33% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+109.33% | 662M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-0.29% | 21.78B | |
-9.28% | 18.09B | |
-41.70% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Dianthus Therapeutics, Inc. announced that it has received $71.987749 million in funding from a group of investors